Starling Oncology, Inc.
STLN · XNASCIK 1799191fmd_16CAKNWEFK1WDP7ETXQSP0MFBDServices · Services-Offices & Clinics of Doctors of MedicineTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 188 | 203 | 252 | 324 | 393 | 503 |
| Net interest income | – | (0) | (4) | (7) | – | – |
| Selling, general and administrative | 42 | 83 | 120 | 114 | 108 | 106 |
| Operating income | (8) | (46) | (82) | (77) | (60) | (36) |
| Interest expense | 0 | 0 | – | 7 | 7 | 11 |
| Interest and investment income | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (7) | 34 | 82 | (6) | (5) | (25) |
| Income before taxes | (15) | (12) | (0) | (83) | (65) | (61) |
| Income tax expense | (0) | (1) | (0) | (0) | 0 | (0) |
| Net income from continuing operations | (14) | (11) | 0 | (83) | (65) | (61) |
| Net income | (14) | (11) | 0 | (83) | (65) | (61) |
| Net income to common shareholders | – | (11) | 0 | (68) | (53) | (50) |